Literature DB >> 21262069

Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions.

Irina Cleemput1, Mattias Neyt, Nancy Thiry, Chris De Laet, Mark Leys.   

Abstract

BACKGROUND: In many countries, the incremental cost-effectiveness ratio (ICER) is used to assess whether an intervention is worth its costs. At the same time, policy makers often feel uncomfortable with refusing reimbursement of any intervention purely on the basis of the fact that the ICER exceeds a specific threshold value. Reluctance to define a single threshold value for the ICER seems to have been stronger in social security systems than in national healthcare services systems. This study explores how basic differences between healthcare systems impact upon the potential usefulness of an ICER threshold value.
METHODS: This study is a narrative review of literature about the theoretical foundations of the ICER threshold value approach and its practical relevance in different types of healthcare systems.
RESULTS: A single ICER threshold value cannot be maintained, defined, or measured and should not be used as a policy-making tool. None of the solutions presented up until now to make the ICER threshold approach a valuable policy-making tool overcome the important weaknesses of the approach.
CONCLUSIONS: ICERs and ICER threshold values are insufficient for assessing interventions' value for money. Rather, they should be considered as one element in the decision-making process. Complete rationalization of the decision-making process by means of quantitative decision criteria is undesirable and not feasible. Increasing transparency in the criteria used for a decision and explicitness about the relative importance of each criterion should, therefore, be the major goal.

Mesh:

Year:  2011        PMID: 21262069     DOI: 10.1017/S0266462310001194

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  37 in total

1.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 2.  Current status of cost utility analyses in total joint arthroplasty: a systematic review.

Authors:  Benedict U Nwachukwu; Kevin J Bozic; William W Schairer; Jaime L Bernstein; David S Jevsevar; Robert G Marx; Douglas E Padgett
Journal:  Clin Orthop Relat Res       Date:  2014-09-30       Impact factor: 4.176

3.  Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis.

Authors:  Jean-Hugues Salmon; Anne-Christine Rat; Isabelle Charlot-Lambrecht; Jean-Paul Eschard; Damien Jolly; Bruno Fautrel
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

4.  Cost-Effectiveness of Preventing Depression Among At-Risk Youths: Postintervention and 2-Year Follow-Up.

Authors:  Frances L Lynch; John F Dickerson; Gregory N Clarke; William R Beardslee; V Robin Weersing; Tracy R G Gladstone; Giovanna Porta; David A Brent; Tami L Mark; Lynn L DeBar; Steven D Hollon; Judy Garber
Journal:  Psychiatr Serv       Date:  2019-01-03       Impact factor: 3.084

5.  Should there be a female age limit on public funding for assisted reproductive technology?

Authors:  Drew Carter; Amber M Watt; Annette Braunack-Mayer; Adam G Elshaug; John R Moss; Janet E Hiller
Journal:  J Bioeth Inq       Date:  2013-01-04       Impact factor: 1.352

6.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

7.  Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria.

Authors:  László Gulácsi; Alexandru M Rotar; Maciej Niewada; Olga Löblová; Fanni Rencz; Guenka Petrova; Imre Boncz; Niek S Klazinga
Journal:  Eur J Health Econ       Date:  2014-05-16

8.  HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain.

Authors:  L Gulácsi; M Péntek
Journal:  Eur J Health Econ       Date:  2014-09

9.  Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.

Authors:  C Camps-Herrero; L Paz-Ares; M Codes; R López-López; A Antón-Torres; P Gascón-Vilaplana; V Guillem-Porta; A Carrato; J J Cruz-Hernández; C Caballero-Díaz; A Blasco-Cordellat; J A Moreno-Nogueira; E Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2014-06-13       Impact factor: 3.405

Review 10.  Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Authors:  Praveen Thokala; Jessica Ochalek; Ashley A Leech; Thaison Tong
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.